The authorities will start the review process to evaluate the data submitted by Medivir. The outcome of this review is expected to be received in the late part of the third quarter of 2009.
Lipsovir is a topical product for the prevention and treatment of cold sores. Lipsovir is a patented combination of hydrocortisone (an anti-inflammatory agent) and acyclovir (an antiviral agent) in a proprietary cream base developed by Medivir.